AKT1 and hepatocellular carcinoma: This may sensitize HCC cells to sorafenib by promoting mTOR (target of rapamycin) ubiquitination via interacting with FBXW7, inhibiting the classical PI3K (phosphoinositide 3-kinase)/AKT/mTOR pathway in HCC pathogenesis, and ultimately inhibiting HCC cell proliferation.52